Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 23; no. 8; p. 403
• Main Authors: Wang, Fengrong, Huang, Xiaojun, Ren, Hanyun, Zhang, Yaochen, Xu, Lanping, Chen, Yuhong, Liu, Kaiyan, Guo, Nailan, Lu, Daopei
• Format: Journal Article
• Language: Chinese
• Published: China 01.08.2002
• Subjects: Acute Disease; Adolescent; Adult; Child; Female; Follow-Up Studies; Graft vs Host Disease - etiology; Hematologic Neoplasms - mortality; Hematologic Neoplasms - therapy; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Male; Middle Aged; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome
• ISSN: 0253-2727

To investigate the application of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in the treatment of hematologic malignancies. Between October 1995 and August 2001, fifty-one patients with hematologic malignancies (median age 34 years, range 5.5 approximately 52 years) received allo-PBSCT from HLA-identical (50) or 1-antigen mismatched sibling donors with conditioning regimens of TBI + CY or modified BU/CY2. Thirty-one patients were acute leukemia (AL) (15 in CR(1), 7 in CR(2) or greater, 10 in relapse including 2 relapse after allo-BMT and the other one never achieved remission); 12 chronic myeloid leukemia (CML) (CP 5, AP 2, BC 4 and relapse after allo-BMT 1); 7 MDS (RAEB 1, RAEB-T 1, AL secondary to MDS 5); Burkitt's lymphoma 1. A combination of cyclosporine and methotrexate was administered for GVHD prophylaxis. All patients were engrafted. The median time (range) to neutrophil >/= 0.5 x 10(9)/L and platelet >/= 20 x 10(9)/L was 14 (10 approximately 20) and 11 (7 approximately 45) days